Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026)
Inhibikase Therapeutics (IKT) posted Other Non-Current Liabilities of $400,000 for Q2 2026, unchanged from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn |
| 10 | Inhibikase Therapeutics | 284.55 Mn | -300.92 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2025 | 4.44 Mn |
API Access
Inhibikase Therapeutics Other Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-non-current-liabilities", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();